Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry

  • Public Health
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

To analyse the cost-effectiveness, in daily clinical practice, of the strategy of treating to the target of clinical remission (CR) in patients with established rheumatoid arthritis (RA), after 2 years of treatment with biological therapy. Adult patients with established RA were treated with biological therapy and followed up for 2 years by a multidisciplinary team responsible for their clinical management. Treatment effectiveness was evaluated by the DAS28 score. The direct costs incurred during this period were quantified from the perspective of the healthcare system. We calculated the cost-effectiveness of obtaining a DAS28 < 2.6, considered as CR. The study included 144 RA patients treated with biological therapies. After 2 years of treatment, 32.6% of patients achieved CR. The mean cost of achieving CR at 2 years was 79,681 ± 38,880 euros. The strategy of treatment to the target of CR is considered the most effective, but in actual clinical practice in patients with established RA, it has a high cost.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229

    Article  PubMed  PubMed Central  Google Scholar 

  2. Carbonell J, Cobo T, Balsa A, Descalzo MA, Carmona L (2008) The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology 47:1088–1092

    Article  CAS  PubMed  Google Scholar 

  3. Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509

    Article  CAS  PubMed  Google Scholar 

  4. Smolen JS (2012) Treat-to-target: rationale and strategies. Clin Exp Rheumatol 30(Suppl. 73):S2–S6

    PubMed  Google Scholar 

  5. Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J (2010) Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology 49:2154–2164

    Article  PubMed  Google Scholar 

  6. Soubrier M, Lukas C, Sibilia J et al (2011) Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 70:611–615

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Schipper LG, Vermeer M, Kuper HH et al (2012) A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 71:845–850

    Article  CAS  PubMed  Google Scholar 

  8. Vermeer M, Kievit W, Kuper HH et al (2013) Treating to the target of remission in early rheumatoid arthritis is cost effective: results of the DREAM-registry. BMC Musculoskelet Disord 14:350

    Article  PubMed  PubMed Central  Google Scholar 

  9. Deighton C, O’Mahony R, Tosh J, Turner C, Rudolf M, Guideline Development Group (2009) Management of rheumatoid arthritis: summary of NICE guidance. BMJ 338:b702

    Article  PubMed  PubMed Central  Google Scholar 

  10. Pope JE, Haraoui B, Rampakakis E et al (2013) Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis Care Res 65:1401–1409

    Article  CAS  Google Scholar 

  11. Cárdenas M, de la Fuente S, Font P et al (2016) Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: Results of the CREATE registry. Rheumatol Int 36:231–241

    Article  CAS  PubMed  Google Scholar 

  12. Rodríguez-Valverde V, Cáliz Cáliz R, Álvaro-Gracia Álvaro JM et al (2006) III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide. Reumatol Clin 2:S52–S59

    Article  PubMed  Google Scholar 

  13. Prevoo MLL, Van‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48

    Article  CAS  PubMed  Google Scholar 

  14. Ruiz-Montesinos MD, Hernández-Cruz B, Ariza-Ariza R, Carmona L, Ballina J, Navarro-Sarabia F (2005) Análisis de costes en una cohorte de enfermos con artritis reumatoide atendidos en área especializada de reumatología en España. Reumatol Clin 1:193–199

    Article  CAS  PubMed  Google Scholar 

  15. Lajas C, Abasolo L, Bellajdel B et al (2003) Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 49:64–70

    Article  PubMed  Google Scholar 

  16. Radner H, Smolen J, Alehata D (2014) Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther 16:R56

    Article  PubMed  PubMed Central  Google Scholar 

  17. Turchetti G, Scalone L, Della Casa Alberighi O et al (2012) The rationale of pharmacoeconomic analysis in rheumatologic indications. Clin Exp Rheumatol 30:S64–S71

    PubMed  Google Scholar 

  18. Schoels M, Wong J, Scott DL et al (2010) Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:995–1003

    Article  PubMed  Google Scholar 

  19. Van Der Velde G, Pham B, Machado M et al (2011) Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res 1:65–78

    Article  Google Scholar 

  20. Huscher D, Mittendorf T, von Hinüber U et al (2015) Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis 74:738–745

    Article  PubMed  Google Scholar 

  21. Benuci M, Rogai V, Atzeni F, Hammen V, Sarzti-Puttini P, Migliore A (2016) Costs associated with rheumatoid arthritis in Italy: past, present, and future. ClinicoEcon Outcomes Res 8:33–41

    Article  Google Scholar 

  22. Kobelt G (2014) Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved. Value Health 17:537–544

    Article  PubMed  Google Scholar 

  23. Smolen JS, Nash P, Durez P et al (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381:918–929

    Article  CAS  PubMed  Google Scholar 

  24. González-Alvaro I, Martínez-Fernández C, Dorantes-Calderón B et al (2015) Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology 54:1200–1209

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Mª Dolores Aguilar-Conesa for technical assistance.

Author information

Authors and Affiliations

  1. Pharmacy Department, Reina Sofía Universitary Hospital, University of Córdoba, Córdoba, Spain

    M. Cárdenas, S. de la Fuente & J. R. Del Prado

  2. Rheumatology Department, Reina Sofía Universitary Hospital, IMIBIC/University of Córdoba, Córdoba, Spain

    M. C. Castro-Villegas, M. Romero-Gómez, D. Ruiz-Vílchez, J. Calvo-Gutiérrez, A. Escudero-Contreras, E. Collantes-Estévez & P. Font

Authors
  1. M. Cárdenas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. de la Fuente
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. C. Castro-Villegas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Romero-Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Ruiz-Vílchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Calvo-Gutiérrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Escudero-Contreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. R. Del Prado
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E. Collantes-Estévez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P. Font
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Cárdenas.

Ethics declarations

Conflict of interest

M. Cárdenas, P. Font, M. C. Castro-Villegas and E. Collantes-Estévez report grants, consulting fees, or lecture fees from MSD, Pfizer or AbbVie, none of which were related to the present work. S. De la Fuente, M. Romero-Alonso, J. Calvo-Gutiérrez, A. Escudero-Contreras, and J. R. Del Prado have no conflict of interest.

Ethical standard

The study meets the standards of Good Clinical Practice, the principles of the Declaration of Helsinki and Order SAS 347/2009 of December 16, which develops guidelines on observational post-authorisation studies for drugs used in humans in Spain. Patient data are coded to maintain anonymity in the study and to prevent their identification by third parties. The study was approved by the Ethical Committee of the Reina Sofia University Hospital of Cordoba.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cárdenas, M., de la Fuente, S., Castro-Villegas, M.C. et al. Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry. Rheumatol Int 36, 1627–1632 (2016). https://doi.org/10.1007/s00296-016-3583-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-016-3583-3

Keywords

Search

Navigation